Randomised Phase II Pilot Study: Induction Chemotherapy With Docetaxel, Cisplatin and Cetuximab Versus Docetaxel, Cisplatin and 5 FU Followed by Radiotherapy With Cetuximab for Locally Advanced or Not Resectable Carcinoma of the Head and Neck
Latest Information Update: 30 May 2022
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin; Docetaxel; Fluorouracil
- Indications Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms HNO-2
- 03 Feb 2021 Status changed from active, no longer recruiting to completed.
- 27 Apr 2020 Planned End Date changed from 1 Jun 2020 to 1 Jan 2022.
- 27 Apr 2020 Planned primary completion date changed from 1 Jun 2020 to 1 Jan 2021.